A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Sponsor: |
EMD Serono Research & Development Institute, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ6154 |
U.S. Govt. ID: |
NCT02745145 |
Contact: |
Elana Bernstein: 212-305-4308 / ejb2153@cumc.columbia.edu |
The purpose of this study is to determine the effectiveness and safety of a study drug called abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study will also look at the following: How the study drug affects other symptoms of SSc-ILD -How safe the study drug is (i.e. if there are any side effects) -How the study drug affects the skin in patients with SSc-ILD who also have extensive skin involvement (a condition called diffuse cutaneous SSc or dcSSc) -How the study drug affects quality of life -How the body absorbs, breaks down, and gets rid of the study drug
This study is closed
Investigator
Elana Bernstein, MD
Have you been diagnosed with systemic sclerosis (SSc)? |
Yes |
No |